Genzyme   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Boston MA United States (1981)
Status: Acquired by Sanofi-Aventis (2011)

Organization Overview

First Clinical Trial
1995
NCT00140634
First Marketed Drug
1991
alglucerase (ceredase)
First NDA Approval
1991
alglucerase (ceredase)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BioMarin/Genzyme LLC | Corp. GCP Compliance - Clinical Affairs, Genzyme Japan K.K. | Diacrin/Genzyme Corporation LLC | GENZYME | Genzyme, a Sanofi Company | Genzyme Coorporation | GENZYME CORP | Genzyme Europe B.V. | Genzyme Europe, B.V.